| Date |
Title (click title to view article) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5/6/2008 |
ZymoGenetics Reports First Quarter 2008 Financial Results |
| 4/30/2008 |
ZymoGenetics Presents Positive Results from RECOTHROM(TM) Thrombin, topical (Recombinant) Spray Study in Burn Patients |
| 4/30/2008 |
Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis |
| 4/28/2008 |
ZymoGenetics to Host Conference Call and Webcast on May 6, 2008 to Discuss 2008 First Quarter Financial Results |
| 4/23/2008 |
ZymoGenetics to Webcast Presentation at Morgan Stanley Conference |
| 3/11/2008 |
ZymoGenetics to Webcast Presentations at Two Conferences |
| 2/13/2008 |
ZymoGenetics Reports Fourth Quarter and Year End 2007 Financial Results |
| 2/4/2008 |
ZymoGenetics to Host Conference Call and Webcast on February 13, 2008 to Discuss 2007 Year-end Financial Results |
| 1/30/2008 |
ZymoGenetics to Webcast Presentation at Merrill Lynch Conference |
| 1/17/2008 |
ZymoGenetics Will Hold Conference Call Today at 4:15 p.m. Eastern Time to Discuss the Approval of RECOTHROM(TM) Thrombin, Topical (Recombinant) |
| 1/17/2008 |
FDA Approves ZymoGenetics' RECOTHROM(TM) Thrombin, topical (Recombinant) |
| 1/15/2008 |
ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE |
| 1/11/2008 |
ZymoGenetics to Webcast Presentation at Stanford Group Healthcare Conference |
| 1/8/2008 |
ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined with Nexavar(R) |
| 12/27/2007 |
ZymoGenetics to Webcast Presentation at JPMorgan Healthcare Conference |
| 12/18/2007 |
ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma |
| 12/13/2007 |
ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of Atacicept in Lupus Nephritis |
| 12/11/2007 |
ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data |
| 12/10/2007 |
ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma |
| 12/5/2007 |
ZymoGenetics to Host Analyst & Investor Briefing on December 13, 2007 |
| 12/4/2007 |
ZymoGenetics to Present at American Society of Hematology Annual Meeting |
| 11/21/2007 |
ZymoGenetics to Webcast Presentation at Piper Jaffray Health Care Conference |
| 10/31/2007 |
ZymoGenetics Reports Third Quarter 2007 Financial Results |
| 10/25/2007 |
ZymoGenetics to Host Conference Call and Webcast on October 31, 2007 to Discuss Third Quarter Results |
| 10/23/2007 |
ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R) |
| 10/5/2007 |
ZymoGenetics to Webcast Presentation At BIO Investor Forum |
| 10/4/2007 |
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis |
| 9/6/2007 |
ZymoGenetics to Webcast Presentation at Two Upcoming Conferences |
| 8/22/2007 |
ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin |
| 8/1/2007 |
ZymoGenetics Reports Second Quarter 2007 Financial Results |
| 7/25/2007 |
ZymoGenetics to Host Conference Call and Webcast on August 1, 2007 to Discuss Q2 2007 Financial Results |
| 7/2/2007 |
ZymoGenetics Announces Senior Management Promotions |
| 6/19/2007 |
ZymoGenetics Will Hold Conference Call on June 19 at 8:30 a.m. Eastern Time to Discuss rThrombin Collaboration with Bayer HealthCare |
| 6/19/2007 |
ZymoGenetics Establishes Global Collaboration With Bayer HealthCare for Development and Commercialization of Recombinant Human Thrombin |
| 6/4/2007 |
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia |
| 5/29/2007 |
ZymoGenetics Announces Upcoming Presentations at ASCO |
| 5/17/2007 |
ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences |
| 5/2/2007 |
ZymoGenetics Reports First Quarter 2007 Financial Results |
| 4/26/2007 |
ZymoGenetics to Host Conference Call and Webcast on May 2, 2007 to Discuss Q1 2007 Financial Results |
| 4/25/2007 |
ZymoGenetics to Webcast Presentation at Morgan Stanley Healthcare Conference |
| 3/12/2007 |
ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences |
| 3/7/2007 |
ZymoGenetics Provides Update on rhThrombin Development Plans |
| 2/26/2007 |
ZymoGenetics to Webcast Presentation at RBC Dain Rauscher Northwest Investor Conference |
| 2/15/2007 |
FDA Accepts ZymoGenetics' Recombinant Human Thrombin Application for Review |
| 2/15/2007 |
ZymoGenetics Reports Fourth Quarter and Year End 2006 Financial Results |
| 2/7/2007 |
ZymoGenetics to Host Conference Call and Webcast on February 15, 2007 to Discuss 2006 Year-end Financial Results |
| 2/1/2007 |
ZymoGenetics to Webcast Presentations at Two Upcoming Investor Conferences |
| 1/30/2007 |
ZymoGenetics Begins Clinical Trial for PEG-Interferon lambda as Potential Treatment for Viral Infection |
| 1/4/2007 |
ZymoGenetics to Highlight Development Programs at JP Morgan Healthcare Conference |
| 12/20/2006 |
ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis |
| 12/18/2006 |
ZymoGenetics Submits Biologics License Application to the FDA for rhThrombin as an Aid to Controlling Bleeding During Surgery |
| 12/14/2006 |
ZymoGenetics Highlights Development Programs at Annual Analyst & Investor Briefing |
| 12/12/2006 |
ZymoGenetics Presents Results From Two Atacicept Phase 1b Clinical Trials in B-Cell Cancer |
| 12/6/2006 |
ZymoGenetics to Review Development Programs at Analyst & Investor Briefing |
| 11/21/2006 |
ZymoGenetics to Highlight Development Programs at Piper Jaffray Conference |
| 11/13/2006 |
ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus |
| 11/10/2006 |
ZymoGenetics to Review Development Programs at Credit Suisse Conference |
| 11/1/2006 |
ZymoGenetics Reports Third Quarter 2006 Financial Results |
| 11/1/2006 |
Webcast Alert: ZymoGenetics, Inc. Announces Its Zymogenetics Q3 2006 Financial Results Conference Call Webcast |
| 10/25/2006 |
ZymoGenetics to Host Conference Call and Webcast on November 1, 2006 to Discuss Third Quarter Results |
| 10/17/2006 |
ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer |
| 9/20/2006 |
ZymoGenetics to Highlight Development Programs at UBS Global Life Sciences Conference |
| 9/18/2006 |
ZymoGenetics Discusses Detailed Results From Successful Phase 3 Trial Evaluating rhThrombin as a Potential Treatment for Surgical Bleeding |
| 9/13/2006 |
ZymoGenetics to Review Detailed rhThrombin Phase 3 Trial Results at Analyst & Investor Briefing |
| 9/5/2006 |
ZymoGenetics Reports Positive Results From Pivotal Phase 3 Clinical Trial of rhThrombin |
| 9/5/2006 |
ZymoGenetics to Highlight Development Programs at Upcoming Bear Stearns Healthcare Conference |
| 8/14/2006 |
ZymoGenetics Files Lawsuit Against Bristol-Myers Squibb for Infringement of Fusion Protein Patents |
| 8/3/2006 |
ZymoGenetics Reports Second Quarter 2006 Financial Results |
| 7/25/2006 |
ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus |
| 7/12/2006 |
ZymoGenetics Begins Phase 1 Trial With IL-21 and Rituxan(R) in Patients With Non-Hodgkin's Lymphoma |
| 6/26/2006 |
ZymoGenetics and Serono Present Positive Results of TACI-Ig Phase 1b Trial in Rheumatoid Arthritis at EULAR Meeting |
| 6/20/2006 |
ZymoGenetics Completes Enrollment for rhThrombin Phase 3 Trial |
| 6/7/2006 |
ZymoGenetics to Highlight Development Programs at Pacific Growth Equities Investor Conference |
| 6/5/2006 |
ZymoGenetics Reports Encouraging IL-21 Phase 1b Results in Metastatic Melanoma and Renal Cell Cancer Presented at ASCO Meeting |
| 5/11/2006 |
ZymoGenetics to Highlight Development Programs at Two Upcoming Investor Conferences |
| 5/4/2006 |
ZymoGenetics Reports First Quarter 2006 Financial Results |
| 5/3/2006 |
ZymoGenetics Names Vaughn Himes Senior Vice President of Technical Operations |
| 5/1/2006 |
ZymoGenetics to Highlight Development Programs at Morgan Stanley Global Healthcare Unplugged Conference |
| 4/25/2006 |
ZymoGenetics Names Michael Dwyer Senior Vice President of Marketing and Sales |
| 3/15/2006 |
ZymoGenetics to Highlight Development Programs at Invest Northwest Conference |
| 3/13/2006 |
Dr. Judith Hemberger Joins ZymoGenetics Board of Directors |
| 3/2/2006 |
ZymoGenetics to Highlight Development Programs at Lehman Brothers Investor Conference |
| 2/15/2006 |
George B. Rathmann, Ph.D. to Retire from ZymoGenetics Board of Directors |
| 2/10/2006 |
ZymoGenetics to Highlight Development Programs at Upcoming BIO CEO & Investor Conference |
| 2/9/2006 |
ZymoGenetics Reports Fourth Quarter and Year End 2005 Financial Results |
| 2/2/2006 |
ZymoGenetics to Highlight Development Programs at Upcoming Merrill Lynch Investor Conference |
| 1/10/2006 |
ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis |
| 1/5/2006 |
ZymoGenetics to Highlight Development Programs and Discuss Preliminary Findings from TACI-Ig Phase 1b Clinical Trial in RA at Upcoming Investor Conference |
| 12/12/2005 |
ZymoGenetics Announces Presentation of TACI-Ig Phase 1 Preliminary Findings in Multiple Myeloma at American Society of Hematology Meeting |
| 12/8/2005 |
ZymoGenetics Highlights Development Programs at Analyst & Investor Briefing |
| 11/30/2005 |
ZymoGenetics to Highlight Development Programs at Analyst & Investor Briefing in New York City; Presentations to be webcast on December 8, 2005 |
| 11/14/2005 |
ZymoGenetics Presents IL-21 Clinical Study Results at International Society for Biological Therapy of Cancer Conference |
| 11/3/2005 |
ZymoGenetics Reports Third Quarter 2005 Financial Results |
| 11/2/2005 |
ZymoGenetics to Highlight Development Programs at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference |
| 10/27/2005 |
ZymoGenetics Begins Phase 3 Clinical Study with Recombinant Human Thrombin; Conference Call Today at 11:00 A.M. Eastern |
| 10/18/2005 |
Novo Nordisk Begins Phase 1 Study With rFXIII In Cardiac Surgery; Milestone Payment Earned By ZymoGenetics |
| 10/5/2005 |
FDA Grants Orphan Drug Designation to ZymoGenetics' IL-21 for Treatment of Melanoma |
| 9/16/2005 |
ZymoGenetics to Highlight Development Programs at Delafield Hambrecht -- WBBA Biotechnology MedTech Forum |
| 9/7/2005 |
ZymoGenetics to Highlight Development Programs at Upcoming Conferences |
| 8/10/2005 |
ZymoGenetics Presents Aggregate Phase 2 Results for Recombinant Human Thrombin |
| 8/4/2005 |
ZymoGenetics Announces Pricing of Public Offering of Common Stock |
| 7/28/2005 |
ZymoGenetics Reports Second Quarter 2005 Financial Results |
| 7/28/2005 |
ZymoGenetics Announces Proposed Public Offering of Common Stock Under Shelf Registration Statement |
| 7/27/2005 |
ZymoGenetics Names Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer; Cancer Therapeutics Veteran to Oversee Clinical Development |
| 6/20/2005 |
ZymoGenetics' Recombinant Human Thrombin Clinical Trial Results Presented at Vascular Surgeons' Annual Meeting |
| 6/17/2005 |
ZymoGenetics Files Form S-3 Shelf Registration Statement |
| 6/6/2005 |
ZymoGenetics to Highlight Development Programs at Pacific Growth Equities Healthcare Conference; Webcast Presentation on June 7, 2005 |
| 5/23/2005 |
ZymoGenetics to Highlight Development Programs at Needham Biotechnology Conference; Webcast Presentation on May 26, 2005 |
| 5/16/2005 |
ZymoGenetics Interleukin 21 Phase 1 Data Presented at ASCO Annual Cancer Meeting; Interim Results Show Potential to Treat Metastatic Melanoma and Renal Cell Carcinoma |
| 5/12/2005 |
ZymoGenetics to Present at Banc of America Securities Health Care Conference; Webcast of Presentation on Thursday, May 19, 2005 |
| 5/9/2005 |
ZymoGenetics to Present at ASCO Annual Meeting; Three IL-21 Presentations to Be Given at Cancer Meeting |
| 5/5/2005 |
ZymoGenetics Reports First Quarter 2005 Financial Results; Momentum Continues with Three Product Candidates in Clinical Development |
| 4/29/2005 |
ZymoGenetics to Highlight Development Programs at Deutsche Bank Healthcare Conference; Webcast Presentation on May 3, 2005 |
| 4/19/2005 |
ZymoGenetics to Highlight Development Programs at Invest Northwest CEO & Investor Forum; Webcast Presentation on April 26, 2005 |
| 4/4/2005 |
David H. MacCallum Appointed to ZymoGenetics Board of Directors; Dr. Bruce L.A. Carter Named Chairman of the Board |
| 3/24/2005 |
ZymoGenetics to Highlight Development Programs at Lehman Brothers Global Healthcare Conference; Webcast Presentation on March 30, 2005 |
| 2/17/2005 |
ZymoGenetics to Highlight Development Programs at BIO CEO and Investor Conference and SunTrust Robinson Humphrey Therapeutics Conference |
| 2/10/2005 |
ZymoGenetics Reports Fourth Quarter and Year End 2004 Financial Results; Highlights Include Pipeline Advancement, Strategic Transactions and Stronger Financial Position |
| 2/9/2005 |
ZymoGenetics Announces Results of Phase 2 Clinical Trials with Recombinant Human Thrombin; Company Reaffirms Plans to Move Forward with Phase 3 Clinical Program |
| 2/3/2005 |
ZymoGenetics to Highlight Development Programs and Preliminary Phase 2 rhThrombin Findings at Merrill Lynch Global Pharma, Biotech and Medical Device Conference |
| 1/5/2005 |
ZymoGenetics to Highlight Development Programs at 23rd Annual JP Morgan Healthcare Conference and Piper Jaffray Annual Healthcare Conference |
| 12/10/2004 |
ZymoGenetics Highlights Development Programs at Analyst & Investor Briefing; Review of Additional Indications for Development Candidates and Financial Strength |
| 12/1/2004 |
ZymoGenetics To Offer Development Program Updates at Analyst & Investor Briefing |
| 11/10/2004 |
ZymoGenetics to Highlight Development Programs at Credit Suisse First Boston Healthcare Conference and ZymoGenetics Analyst & Investor Briefing |
| 11/8/2004 |
ZymoGenetics Presents Results of Healthy Volunteer Study with TACI-Ig at 4th International Congress on Autoimmunity |
| 11/4/2004 |
ZymoGenetics Reports Third Quarter 2004 Financial Results; Major Business Development Initiatives Enable Greater Focus on Genomics-Based Pipeline |
| 10/5/2004 |
ZymoGenetics Licenses Recombinant Factor XIII to Novo Nordisk |
| 10/4/2004 |
ZymoGenetics and Serono to Begin TACI-Ig Clinical Studies in B-Cell Malignancies |
| 9/9/2004 |
ZymoGenetics to Highlight Development Programs at Bear Stearns Annual Healthcare Conference and UBS Global Life Sciences Conference |
| 9/8/2004 |
ZymoGenetics and Serono Establish Broad Strategic Research, Development and Commercialization Alliance |
| 9/7/2004 |
ZymoGenetics Names Douglas E. Williams, Ph.D., Executive Vice President and Chief Scientific Officer |
| 8/30/2004 |
ZymoGenetics Announces Start of TACI-Ig Clinical Study in Rheumatoid Arthritis; Second Phase 1b Study Initiated in Patients with Autoimmune Disease |
| 8/5/2004 |
ZymoGenetics Reports Second Quarter 2004 Financial Results |
| 7/27/2004 |
ZymoGenetics Announces Start of TACI-Ig Clinical Study in Lupus Patients; Phase 1b Study in Autoimmune Disease with Unmet Medical Needs |
| 7/6/2004 |
ZymoGenetics Licenses Ex-North American Rights to Three Proteins with Antiviral and Anti-Inflammatory Disease Therapeutic Potential to Novo Nordisk |
| 7/1/2004 |
ZymoGenetics Appoints James Harper to Board of Directors; Seasoned Pharmaceutical Executive Offers Marketing and Operations Expertise |
| 6/11/2004 |
ZymoGenetics to Highlight Development Programs at Needham & Company Biotechnology Conference; Webcast of Presentation on Thursday, June 17, 2004 |
| 6/9/2004 |
ZymoGenetics Receives Notice from Novo Nordisk to Extend Option and License Agreement |
| 6/7/2004 |
ZymoGenetics Presents Preclinical Interleukin 21/Antibody-Based Cancer Therapy Data at ASCO; Preclinical Studies Suggest Clinical Utility in Combination Cancer Therapy |
| 6/3/2004 |
ZymoGenetics to Highlight Development Programs at Pacific Growth Equities Conference |
| 5/20/2004 |
ZymoGenetics Licenses Metabolic Disease Target Patent Estate to Amgen |
| 5/13/2004 |
ZymoGenetics to Highlight Development Programs at Banc of America Securities Conference; Webcast of Presentation on Wednesday, May 19, 2004 |
| 5/7/2004 |
ZymoGenetics to Highlight Development Programs at Upcoming Investor Conferences; Webcast of Presentations on Tuesday, May 11 and Thursday, May 13, 2004 |
| 5/6/2004 |
ZymoGenetics Reports First Quarter 2004 Financial Results |
| 4/19/2004 |
ZymoGenetics Begins Phase 2 Clinical Studies with Recombinant Human Thrombin; Phase 1 Patient Treatment Completed with Innovative Surgical Hemostatic Agent |
| 4/5/2004 |
ZymoGenetics to Begin Clinical Study with Interleukin 21; FDA gives go ahead to proceed with Phase 1 cancer study |
| 3/16/2004 |
ZymoGenetics and Novo Nordisk Sign License for Interleukin 20; Novo Nordisk Obtains North American Development Rights |
| 3/9/2004 |
ZymoGenetics Presents Data Supporting FGF18 as a Therapy for Osteoarthritis; Data Presented at the 2004 Annual Meeting of the Orthopaedic Research Society |
| 2/26/2004 |
ZymoGenetics to Highlight Development Programs at Lehman Brothers Conference; Webcast of Presentation on Wednesday, March 3, 2004 |
| 2/18/2004 |
ZymoGenetics to Highlight Development Programs at BIO CEO & Investor Conference; Webcast of presentation on Wednesday, February 25, 2004 |
| 2/12/2004 |
ZymoGenetics Reports Fourth Quarter and Year End 2003 Financial Results; Three Proteins Advanced to Clinical Testing in 2003 |
| 2/6/2004 |
Company Profile for ZymoGenetics |
| 1/29/2004 |
ZymoGenetics to Highlight Development Programs at Merrill Lynch Conference; Webcast of Presentation on Wednesday, February 4, 2004 |
| 1/22/2004 |
ZymoGenetics to Highlight Development Programs at Piper Jaffray Healthcare Conference; Webcast of Presentation on Tuesday, January 27, 2004 |
| 1/9/2004 |
ZymoGenetics to Highlight Development Programs at JP Morgan Healthcare Conference; Webcast of Presentation on Wednesday, January 14, 2004 |
| 12/11/2003 |
ZymoGenetics Highlights Product Development Activities at Analyst & Investor Briefing -- Three product candidates enter clinical development in 2003 |
| 12/5/2003 |
ZymoGenetics To Hold Analyst & Investor Briefing in New York City on December 11th |
| 12/3/2003 |
ZymoGenetics to Begin Clinical Studies with Recombinant Human Thrombin |
| 11/6/2003 |
ZymoGenetics Reports Third Quarter 2003 Financial Results; Product Development Advancement is Supported by Enhanced Cash Reserves |
| 10/15/2003 |
ZymoGenetics Announces Pricing of Public Offering of Common Stock |
| 10/7/2003 |
ZymoGenetics Announces Proposed Public Offering of Common Stock Under Shelf Registration Statement |
| 10/2/2003 |
ZymoGenetics Signs Manufacturing Agreement with Abbott Laboratories to Produce Recombinant Human Thrombin |
| 9/29/2003 |
ZymoGenetics and Serono Initiate Clinical Trial with TACI-Ig |
| 9/22/2003 |
ZymoGenetics Appoints Dr. Fredrik Henell to Lead Business Development Efforts |
| 9/3/2003 |
ZymoGenetics to Highlight Development Programs at Bear Stearns & Co. Healthcare Conference; Webcast of Presentation on Monday, September 8, 2003 |
| 8/7/2003 |
ZymoGenetics Reports Second Quarter 2003 Financial Results; rFactor XIII Development Progress Highlights Quarter |
| 7/25/2003 |
ZymoGenetics Announces Filing of Shelf Registration Statement |
| 7/17/2003 |
ZymoGenetics Reports New Findings on Anti-thrombotic Activities of CTRP1; Novel Protein Prevents Platelet Thrombosis without Causing Bleeding |
| 7/14/2003 |
ZymoGenetics Demonstrates Anti-tumor Activity with Interleukin-21 |
| 7/14/2003 |
ZymoGenetics Presents Results From Clinical Study with Recombinant Human Factor XIII; Treatment with Recombinant Factor XIII Observed to Be Safe |
| 7/9/2003 |
ZymoGenetics to Review Clinical Trial Data for Recombinant Human Factor XIII |
| 6/4/2003 |
ZymoGenetics Initiates Third Clinical Study with Recombinant Human Factor XIII; Orphan Drug Status for rFactor XIII Granted by the FDA |
| 6/2/2003 |
ZymoGenetics to Highlight Development Programs at Needham & Company Biotechnology Conference; Webcast of presentation on Thursday, June 5, 2003 |
| 5/8/2003 |
ZymoGenetics Reports First Quarter 2003 Financial Results; Initiation of Clinical Trials with rFactor XIII Leads Product Development Activities |
| 2/27/2003 |
ZymoGenetics to Highlight Development Programs at Lehman Brothers Healthcare Conference; Webcast of presentation on Tuesday, March 4, 2003 |
| 2/13/2003 |
ZymoGenetics Reports Fourth Quarter and Year End 2002 Financial Results; Profitable Quarter Results From Lawsuit Settlement Proceeds |
| 2/6/2003 |
BioMimetic Pharmaceuticals and ZymoGenetics Sign Second Licensing Agreement for Clinical Development and Commercialization of PDGF |
| 2/4/2003 |
ZymoGenetics Initiates Clinical Trials and Strengthens Proprietary Position for Recombinant Human Factor XIII |
| 1/30/2003 |
ZymoGenetics to Webcast Presentation at Merrill Lynch Conference; Dr. Bruce Carter will present on Tuesday, February 4th |
| 1/9/2003 |
ZymoGenetics and Novo Nordisk Enter into Preclinical Development Alliance for Interleukin 21; Companies to Share Costs and Preclinical Data Leading up to IND Filing |
| 1/6/2003 |
ZymoGenetics to Highlight Development Programs at JP Morgan H & Q Healthcare Conference |
| 12/23/2002 |
ZymoGenetics and Amgen Settle Patent Infringement Lawsuit for the Rheumatoid Arthritis Drug Enbrel(R) (etanercept |
| 12/3/2002 |
ZymoGenetics Highlights Development Programs at Analyst & Investor Briefing |
| 11/21/2002 |
ZymoGenetics to Hold Analyst & Investor Briefing In New York City on December 3rd |
| 11/7/2002 |
ZymoGenetics Reports Third Quarter 2002 Financial Results |
| 10/9/2002 |
ZymoGenetics Adds Interleukin-21 (IL-21) to Its Product Development Pipeline |
| 10/7/2002 |
ZymoGenetics, Inc. and Alexandria Real Estate Equities, Inc. Complete $52 Million Sale Leaseback Transaction |
| 9/17/2002 |
ZymoGenetics Files Investigational New Drug Application for Recombinant Human Factor XIII to Treat Congenital Deficiency |
| 9/13/2002 |
ZymoGenetics Announces Webcast of Presentation at Bear Stearns 15th Annual Healthcare Conference |
| 8/8/2002 |
ZymoGenetics Reports Second Quarter 2002 Financial Results |
| 7/29/2002 |
ZymoGenetics Announces License Agreement for Interleukin-13 Receptor With Wyeth |
| 7/18/2002 |
ZymoGenetics Receives U.S. Patent on ADAM33 Protein |
| 6/24/2002 |
ZymoGenetics Announces Novo Nordisk A/S Has Converted Its Non-Voting Shares of ZymoGenetics Stock into Voting Shares |
| 6/10/2002 |
ZymoGenetics and Regeneron Sign License Agreement for Ig-Fusion Protein Technology |
| 6/3/2002 |
ZymoGenetics Provides Update on Manufacturing Plans |
| 5/29/2002 |
BioMimetic Pharmaceuticals Initiates Pivotal Clinical Study with Platelet-derived Growth Factor for the Treatment of Periodontal Diseases |
| 5/23/2002 |
ZymoGenetics and Arriva Pharmaceuticals Sign Agreement for Alpha 1-Antitrypsin -US patent covers commercial production of AAT in yeast- |
| 5/8/2002 |
ZymoGenetics Reports First Quarter 2002 Financial Results - Completion of IPO Highlights Quarter - |
| 4/29/2002 |
ZymoGenetics Reports New Preclinical Findings on Zfgf5, a Novel Growth Factor Implicated in Cartilage Repair |
| 3/11/2002 |
ZymoGenetics Reports Fourth Quarter and Year End 2001 Financial Results |
| 3/7/2002 |
ZymoGenetics Files Patent Infringement Suit Against Immunex |
| 2/19/2002 |
ZymoGenetics Announces Webcast of Presentation at the BIO CEO & Investor Conference, Wednesday, February 20, 2002 at 10:20 a.m. ET |
| 2/1/2002 |
ZymoGenetics, Inc. Announces Initial Public Offering of Common Stock |
| 1/4/2002 |
ZymoGenetics Appoints Dr. Mark Young as Senior Vice President, Technical Operations |
| 12/3/2001 |
ZymoGenetics Appoints Robert S. Whitehead as Chief Business Officer |
| 11/9/2001 |
ZymoGenetics to Discuss Novel Therapeutic Approaches for the Treatment of Autoimmune Disease |
| 9/10/2001 |
ZymoGenetics, Inc. Files Registration Statement for an Initial Public Offering of Common Stock |
| 9/4/2001 |
ZymoGenetics and Serono to Collaborate on a Novel Therapeutic Approach for Autoimmune Disease |
| 7/19/2001 |
ZymoGenetics Names George B. Rathmann as Chairman of Board |
| 6/5/2001 |
ZymoGenetics and BioMimetic Pharmaceuticals Sign Licensing Agreement for Clinical Development of PDGF |
| 1/31/2001 |
ZymoGenetics Appoints James A. Johnson as Chief Financial Officer |
| 1/12/2001 |
ZymoGenetics Researchers Identify Novel Protein with Potential Role in Psoriasis |
| 11/2/2000 |
ZymoGenetics Researchers Identify Novel Interleukin that Plays Key Role in Immune System Regulation |
| 10/23/2000 |
Novo Nordisk Completes Private Placement of Shares in ZymoGenetics- ZymoGenetics Launched as Independent Biotechnology Company |
| 10/19/2000 |
ZymoGenetics and Medarex Announce Alliance to Develop Fully Human Antibody Therapeutics |
| 8/16/2000 |
ZymoGenetics Appoints Frank Collins, Ph.D. as Senior Vice President of Research |
| 7/26/2000 |
FibroGen and ZymoGenetics Establish Research Collaboration for Development of Wound Management Products |
| 5/30/2000 |
ZymoGenetics Names George B. Rathmann, Ph.D. and Edward E. Penhoet, Ph.D. to Board of Directors |
| 4/27/2000 |
ZymoGenetics Discovers Potential New Therapy for Autoimmune Diseases |
Back to top
